"","STUDYID","DOMAIN","TSSEQ","TSPARMCD","TSPARM","TSVAL"
"1","CDISCPILOT01","TS",1,"ADDON","Added on to Existing Treatments","Y"
"2","CDISCPILOT01","TS",1,"AGEMAX","Planned Maximum Age of Subjects","No maximum"
"3","CDISCPILOT01","TS",1,"AGEMIN","Planned Minimum Age of Subjects","50 years"
"4","CDISCPILOT01","TS",1,"AGESPAN","Age Group","ADULT (18-65)"
"5","CDISCPILOT01","TS",2,"AGESPAN","Age Group","ELDERLY (> 65)"
"6","CDISCPILOT01","TS",1,"TBLIND","Trial Blinding Schema","DOUBLE BLIND"
"7","CDISCPILOT01","TS",1,"COMPTRT","Comparative Treatment Name","Placebo"
"8","CDISCPILOT01","TS",1,"TCNTRL","Control Type","PLACEBO"
"9","CDISCPILOT01","TS",1,"TDIGRP","Diagnosis Group","Patients with Probable Mild to Moderate Alzheimer’s Disease"
"10","CDISCPILOT01","TS",1,"DOSE","Dose per Administration","54"
"11","CDISCPILOT01","TS",2,"DOSE","Dose per Administration","81"
"12","CDISCPILOT01","TS",1,"DOSFRQ","Dosing Frequency","QD; 12 to 14 hours transdermal application"
"13","CDISCPILOT01","TS",1,"DOSU","Dose Units","mg"
"14","CDISCPILOT01","TS",1,"INDIC","Trial Indication","Mild to Moderate Alzheimer’s Disease"
"15","CDISCPILOT01","TS",1,"TINDTP","Trial Indication Type","TREATMENT"
"16","CDISCPILOT01","TS",1,"LENGTH","Trial Length","26 weeks"
"17","CDISCPILOT01","TS",1,"OBJPRIM","Trial Primary Objective","To determine if there is a statistically significant relationship between the change in both ADAS-Cog and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg])"
"18","CDISCPILOT01","TS",2,"OBJPRIM","Trial Primary Objective","To document the safety profile of the xanomeline TTS."
"19","CDISCPILOT01","TS",1,"OBJSEC","Trial Secondary Objective","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these areas."
"20","CDISCPILOT01","TS",2,"OBJSEC","Trial Secondary Objective","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas."
"21","CDISCPILOT01","TS",3,"OBJSEC","Trial Secondary Objective","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The ADAS-Cog (14) will be used for this assessment."
"22","CDISCPILOT01","TS",4,"OBJSEC","Trial Secondary Objective","To assess the treatment response as a function of Apo E genotype."
"23","CDISCPILOT01","TS",1,"TPHASE","Trial Phase Classification","Phase II Trial"
"24","CDISCPILOT01","TS",1,"PLANSUB","Planned Number of Subjects","300"
"25","CDISCPILOT01","TS",1,"RANDOM","Trial is Randomized","Y"
"26","CDISCPILOT01","TS",1,"ROUTE","Route of Administration","TRANSDERMAL"
"27","CDISCPILOT01","TS",1,"SEXPOP","Sex of Participants","BOTH"
"28","CDISCPILOT01","TS",1,"SPONSOR","Clinical Study Sponsor","CDISCPILOT01"
"29","CDISCPILOT01","TS",1,"TITLE","Trial Title","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer’s Disease."
"30","CDISCPILOT01","TS",1,"TRT","Investigational Therapy or Treatment","Xanomeline"
"31","CDISCPILOT01","TS",1,"TTYPE","Trial Type","SAFETY"
"32","CDISCPILOT01","TS",2,"TTYPE","Trial Type","EFFICACY"
"33","CDISCPILOT01","TS",4,"TTYPE","Trial Type","PHARMACOKINETIC"
